Guidance on the use of over-the-counter proton pump inhibitors for the treatment of GERD
详细信息 查看全文
- 作者：Gerald Holtmann (1)
Marc-André Bigard (2)
Peter Malfertheiner (3)
Roy Pounder (4) - 关键词：Gastroesophageal reflux disease ; GERD ; Guidance ; Omeprazole ; OTC drugs ; Pharmacist ; Proton pump inhibitors
- 刊名：International Journal of Clinical Pharmacy
- 出版年：2011
- 出版时间：June 2011
- 年：2011
- 卷：33
- 期：3
- 页码：493-500
- 全文大小：224KB
- 参考文献：1. Moss SF, Armstrong D, Arnold R, Ferenci P, Fock KM, Holtmann G, McCarthy DM, Moraes-Filho JP, et al. GERD 2003—a consensus on the way ahead. Digestion. 2003;67(3):111-. CrossRef
2. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900-0. quiz 1943. CrossRef
3. Jones R, Armstrong D, Malfertheiner P, Ducrotte P. Does the treatment of gastroesophageal reflux disease (GERD) meet patients-needs? A survey-based study. Curr Med Res Opin. 2006;22(4):657-2. CrossRef
4. Tytgat GN, McColl K, Tack J, Holtmann G, Hunt RH, Malfertheiner P, Hungin AP, Batchelor HK. New algorithm for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2008;27(3):249-6. CrossRef
5. Wilson JF. In the clinic. Gastroesophageal reflux disease. Ann Intern Med. 2008;149(3):ITC2-1-15. quiz ITC12-6.
6. Shaker R, Castell DO, Schoenfeld PS, Spechler SJ. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol. 2003;98(7):1487-3. CrossRef
7. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005;54(5):710-. CrossRef
8. Ruigomez A, Garcia Rodriguez LA, Wallander MA, Johansson S, Graffner H, Dent J. Natural history of gastro-oesophageal reflux disease diagnosed in general practice. Aliment Pharmacol Ther. 2004;20(7):751-0. CrossRef
9. Jacobson BC, Somers SC, Fuchs CS, Kelly CP, Camargo CA Jr. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med. 2006;354(22):2340-. CrossRef
10. El-Serag H, Hill C, Jones R. Systematic review: the epidemiology of gastro-oesophageal reflux disease in primary care, using the UK General Practice Research Database. Aliment Pharmacol Ther. 2009;29(5):470-0. CrossRef
11. Jones R, Armstrong D, Malfertheiner P, Ducrotte P, Colin R. A multinational survey of activities of daily living and GERD in clinical practice: is prescription therapy adequate? Gastroenterology. 2003;124(4):A505. CrossRef
12. Kamolz T, Pointner R. What do heartburn sufferers expect from proton pump inhibitors when prescribed for the first time? Minerva Gastroenterol Dietol. 2004;50(2):143-.
13. Holtmann G, Adam B, Liebregts T. Review article: the patient with gastro-oesophageal reflux disease—lifestyle advice and medication. Aliment Pharmacol Ther. 2004;20(Suppl 8):24-. CrossRef
14. van Pinxteren B, Numans ME, Bonis PA, Lau J. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2006;3:CD002095.
15. Tran T, Lowry AM, El-Serag HB. Meta-analysis: the efficacy of over-the-counter gastro-oesophageal reflux disease therapies. Aliment Pharmacol Ther. 2007;25(2):143-3.
16. Chiba N. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview. Can J Gastroenterol. 1997;11(Suppl B):66B-3B.
17. Inadomi JM, Fendrick AM. PPI use in the OTC era: who to treat, with what, and for how long? Clin Gastroenterol Hepatol. 2005;3(3):208-5. CrossRef
18. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005;100(1):190-00. CrossRef
19. Koop H, Schepp W, Muller-Lissner S, Madisch A, Micklefield G, Messmann H, Fuchs KH, Hotz J. Consensus conference of the DGVS on gastroesophageal reflux. Z Gastroenterol. 2005;43(2):163-. CrossRef
20. Cohen H, Moraes-Filho JP, Cafferata ML, Tomasso G, Salis G, Gonzalez O, Valenzuela J, Sharma P, et al. An evidence-based, Latin-American consensus on gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol. 2006;18(4):349-8. CrossRef
21. Lin SR, Xu GM, Hu PJ, Zhou LY, Chen MH, Ke MY, Yuan YZ, Fang DC, et al. Chinese consensus on gastroesophageal reflux disease (GERD): October 2006, Sanya, Hainan Province, China. J Dig Dis. 2007;8(3):162-. CrossRef
22. Fock KM, Talley NJ, Fass R, Goh KL, Katelaris P, Hunt R, Hongo M, Ang TL, et al. Asia-Pacific consensus on the management of gastroesophageal reflux disease: update. J Gastroenterol Hepatol. 2008;23(1):8-2. CrossRef
23. Kahrilas PJ, Shaheen NJ, Vaezi MF, Hiltz SW, Black E, Modlin IM, Johnson SP, Allen J, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135(4):1383-1. e1381-5. CrossRef
24. Fendrick AM, Shaw M, Schachtel B, Allgood L, Allgood G, Grender J, Peura D. Self-selection and use patterns of over-the-counter omeprazole for frequent heartburn. Clin Gastroenterol Hepatol. 2004;2(1):17-1. CrossRef
25. Miner PB Jr, Allgood LD, Grender JM. Comparison of gastric pH with omeprazole magnesium 20.6?mg (Prilosec OTC) o.m. famotidine 10?mg (Pepcid AC) b.d. and famotidine 20?mg b.d. over 14?days of treatment. Aliment Pharmacol Ther. 2007;25(1):103-. CrossRef
26. Allgood LD, Grender JM, Shaw MJ, Peura DA. Comparison of Prilosec OTC (omeprazole magnesium 20.6?mg) to placebo for 14?days in the treatment of frequent heartburn. J Clin Pharm Ther. 2005;30(2):105-2. CrossRef
27. Shaw MJ, Fendrick AM, Kane RL, Adlis SA, Talley NJ. Self-reported effectiveness and physician consultation rate in users of over-the-counter histamine-2 receptor antagonists. Am J Gastroenterol. 2001;96(3):673-. CrossRef
28. Konturek JW, Beneke M, Koppermann R, Petersen-Braun M, Weing?rtner U. The efficacy of hydrotalcite compared with OTC famotidine in the on-demand treatment of gastroesophageal reflux disease: a non-inferiority trial. Med Sci Monit. 2007;13(1):CR44-.
29. Khan M, Santana J, Donnellan C, Preston C, Moayyedi P. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev 2007;(2):CD003244.
30. Gillen D, McColl KE. Problems related to acid rebound and tachyphylaxis. Best Pract Res Clin Gastroenterol. 2001;15(3):487-5. CrossRef
31. Bate CM, Keeling PW, O’Morain C, Wilkinson SP, Foster DN, Mountford RA, Temperley JM, Harvey RF, et al. Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic, and histological evaluations. Gut. 1990;31(9):968-2. CrossRef
32. Feldman M, Harford WV, Fisher RS, Sampliner RE, Murray SB, Greski-Rose PA, Jennings DE. Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K(+)-ATPase inhibitor: a controlled, double-blind study. Lansoprazole Study Group. Am J Gastroenterol. 1993;88(8):1212-.
33. Vigneri S, Termini R, Leandro G, Badalamenti S, Pantalena M, Savarino V, Di Mario F, Battaglia G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med. 1995;333(17):1106-0. CrossRef
34. Gough AL, Long RG, Cooper BT, Fosters CS, Garrett AD, Langworthy CH. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther. 1996;10(4):529-9. CrossRef
35. Farley A, Wruble LD, Humphries TJ. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Rabeprazole Study Group. Am J Gastroenterol. 2000;95(8):1894-. CrossRef
36. Grimley CE, Constantinides S, Snell CC, Mills JG, Nwokolo CU. Inhibition of intragastric acidity in healthy subjects dosed with ranitidine 75?mg: a comparative study with cimetidine and placebo. Aliment Pharmacol Ther. 1997;11(5):875-. CrossRef
37. Hamilton MI, Sercombe J, Pounder RE. Decrease of intragastric acidity in healthy subjects dosed with ranitidine 75?mg, cimetidine 200?mg, or placebo. Dig Dis Sci. 2002;47(1):54-. CrossRef
38. Holtmeier W, Holtmann G, Caspary WF, Weingartner U. On-demand treatment of acute heartburn with the antacid hydrotalcite compared with famotidine and placebo: randomized double-blind cross-over study. J Clin Gastroenterol. 2007;41(6):564-0. CrossRef
39. Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L. Effect of omeprazole–a gastric proton pump inhibitor–on pentagastrin stimulated acid secretion in man. Gut. 1983;24(4):270-. CrossRef
40. Netzer P, Brabetz-Hofliger A, Brundler R, Flogerzi B, Husler J, Halter F. Comparison of the effect of the antacid Rennie versus low-dose H2-receptor antagonists (ranitidine, famotidine) on intragastric acidity. Aliment Pharmacol Ther. 1998;12(4):337-2. CrossRef
41. Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebo-controlled trial to assess the effects of 8?days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther. 1998;12(11):1079-9. CrossRef
42. Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther. 2003;17(12):1507-4. CrossRef
43. Armstrong D, Veldhuyzen van Zanten SJ, Barkun AN, Chiba N, Thomson AB, Smyth S, Sinclair P, Chakraborty B, et al. Heartburn-dominant, uninvestigated dyspepsia: a comparison of ‘PPI-start-and ‘H2-RA-start-management strategies in primary care–the CADET-HR Study. Aliment Pharmacol Ther. 2005;21(10):1189-02. CrossRef
44. Bytzer P, Morocutti A, Kennerly P, Ravic M, Miller N. Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment. Scand J Gastroenterol. 2006;41(10):1132-0. CrossRef
45. Calabrese C, Liguori G, Gabusi V, Gionchetti P, Rizzello F, Straforini G, Brugnera R, Di Febo G. Ninety-six-hour wireless oesophageal pH monitoring following proton pump inhibitor administration in NERD patients. Aliment Pharmacol Ther. 2008;28(2):250-. CrossRef
46. Revicki DA, Sorensen S, Maton PN, Orlando RC. Health-related quality of life outcomes of omeprazole versus ranitidine in poorly responsive symptomatic gastroesophageal reflux disease. Dig Dis. 1998;16(5):284-1. CrossRef
47. Bardhan KD. Pantoprazole: a new proton pump inhibitor in the management of upper gastrointestinal disease. Drugs Today (Barc). 1999;35(10):773-08.
48. Bayer Antra Fachinformation. German Summary of Product Characteristics, SPC, 2009.
49. McQuaid KR, Laine L. Early heartburn relief with proton pump inhibitors: a systematic review and meta-analysis of clinical trials. Clin Gastroenterol Hepatol. 2005;3(6):553-3. CrossRef
50. R?sch W. Treatment of reflux disease with proton pump inhibitors. Pharm Unserer Zeit. 2005;34(3):210-. CrossRef
51. Lind T, Havelund T, Carlsson R, Anker-Hansen O, Glise H, Hernqvist H, Junghard O, Lauritsen K, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol. 1997;32(10):974-. CrossRef
52. European Medicines Agency. Omeprazole Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Losec_30/WC500070014.pdf. Accessed October 2010.
53. Jones R, Ballard K. Healthcare seeking in gastro-oesophageal reflux disease: a qualitative study. Eur J Gastroenterol Hepatol. 2008;20(4):269-5. CrossRef
54. Oliveria SA, Christos PJ, Talley NJ, Dannenberg AJ. Heartburn risk factors, knowledge, and prevention strategies: a population-based survey of individuals with heartburn. Arch Intern Med. 1999;159(14):1592-. CrossRef
55. Bretagne JF, Honnorat C, Richard-Molard B, Soufflet C, Barthelemy P. Perceptions and practices on the management of gastro-oesophageal reflux disease: results of a national survey comparing primary care physicians and gastroenterologists. Aliment Pharmacol Ther. 2007;25(7):823-3. CrossRef
56. Talley NJ, Vakil NB, Moayyedi P. American Gastroenterological Association technical review on the evaluation of dyspepsia. Gastroenterology. 2005;129(5):1756-0. CrossRef
57. Canadian Agency for Drugs and Technologies in Health. Evidence for PPI use in gastroesophageal reflux disease, dyspepsia, and peptic ulcer disease: scientific report. 2007. Available at: http://www.cadth.ca/media/compus/reports/compus_Scientific_Report_final.pdf. Accessed 16 Sept 2009.
58. Sonnenberg A, El-Serag HB. Clinical epidemiology and natural history of gastroesophageal reflux disease. Yale J Biol Med. 1999;72(2-):81-2.
59. Pondugula K, Wani S, Sharma P. Barrett’s esophagus and esophageal adenocarcinoma in adults: long-term GERD or something else? Curr Gastroenterol Rep. 2007;9(6):468-4. CrossRef
60. Ward EM, Wolfsen HC, Achem SR, Loeb DS, Krishna M, Hemminger LL, DeVault KR. Barrett’s esophagus is common in older men and women undergoing screening colonoscopy regardless of reflux symptoms. Am J Gastroenterol. 2006;101(1):12-. CrossRef
61. Labenz J, Nocon M, Lind T, Leodolter A, Jaspersen D, Meyer-Sabellek W, Stolte M, Vieth M, et al. Prospective follow-up data from the ProGERD study suggest that GERD is not a categorial disease. Am J Gastroenterol. 2006;101(11):2457-2.
62. Stoltey J, Reeba H, Ullah N, Sabhaie P, Gerson L. Does Barrett’s oesophagus develop over time in patients with chronic gastro-oesophageal reflux disease? Aliment Pharmacol Ther. 2007;25(1):83-1.
63. Morgner-Miehlke A, Koop H, Blum AL, Hermans ML, Miehlke S, Labenz J. Symptom- versus endoscopy-based diagnosis and treatment of gastroesophageal reflux disease (GERD). Z Gastroenterol. 2006;44(5):399-10. CrossRef
64. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett’s esophagus? Gastroenterology. 2000;119(2):333-. CrossRef
65. Shaheen N, Ransohoff DF. Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review. JAMA. 2002;287(15):1972-1. CrossRef
66. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102(9):2047-6. quiz 2057. CrossRef
67. Martin E. Proton pump inhibitors in the pharmacy. Pharm Unserer Zeit. 2005;34(3):228-5. CrossRef
68. Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for recurrent / Clostridium difficile infection. Arch Intern Med. 2010;170(9):772-. CrossRef
69. AstraZeneca. Summary of Product Characteristics (Fachinformation Antra Mups 20?mg). 2007.
70. Food and Drug Administration. Public Health Advisory: Updated Safety Information about a drug interaction between Clopidogrel Bisulfate (marketed as Plavix) and Omeprazole (marketed as Prilosec and Prilosec OTC). Available at: http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm190825.htm. Accessed June 2010.
71. European Medicines Agency. Public statement: Interaction between clopidogrel and proton-pump inhibitors. Available at: http://www.ema.europa.eu/humandocs/PDFs/EPAR/Plavix/17494810en.pdf. Accessed June 2010.
72. Labenz J, Petersen KU, Rosch W, Koelz HR. A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther. 2003;17(8):1015-. CrossRef
73. Reilly JP. Safety profile of the proton-pump inhibitors. Am J Health Syst Pharm. 1999;56(23 Suppl 4):S11-.
74. Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE, Chen Z. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch Intern Med. 2010;170(9):765-1. CrossRef - 作者单位：Gerald Holtmann (1)
Marc-André Bigard (2)
Peter Malfertheiner (3)
Roy Pounder (4)
1. Department of Gastroenterology and Hepatology, Princess Alexandra Hospital, University of Adelaide, Adelaide, SA, Australia
2. Service d’Hépatogastroentérologie, H?pital de Brabois—rue du Morvan, Vandoeuvre lès Nancy, France
3. Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Magdeburg, Magdeburg, Germany
4. Department of Medicine, University of London, London, UK - ISSN：2210-7711
文摘
Objective The aim of this paper was to develop a guideline on the over-the-counter management of gastroesophageal reflux disease with proton pump inhibitors (i.e. omeprazole). Setting A meeting of internationally renowned gastroenterologists in January 2009, in Berlin, Germany. Methods An expert panel group of gastroenterologists convened to develop a consensus-based algorithm for pharmacists for over-the-counter (OTC) treatment with proton pump inhibitors (PPIs). Key considerations were the short-term safety and efficacy of PPIs, and the extent of the risk to the sufferer, owing to the treatment not being controlled by a physician. Main outcome measures A consensus-based treatment algorithm for the OTC management of gastroesophageal reflux disease and evidence-based guidance on the use of OTC PPIs. Results As defined by the treatment algorithm, the pharmacist should first confirm the diagnosis based on the presence of typical symptoms and secondly, as a result, rule out general practitioner referral. The third step focuses on the nature, severity and frequency of the symptoms—the patients who might have the highest benefit from a short course (14?days) of OTC PPIs are those with less than three episodes of heartburn and/or acid regurgitation per week. Patients who have three or more episodes per week can use the OTC PPIs but should also be encouraged to visit a physician, and those who already have a diagnostic work-up can use proton pump inhibitors as rescue treatment if they are known responders. Guidance for pharmacists, in the form of questions and answers, summarises the current published clinical experience with PPIs in terms of their efficacy and safety, and optimal treatment schedule. Conclusions Gastroesophageal reflux disease imposes a considerable burden on sufferers. Owing to their accepted efficacy and safety, PPIs are becoming popular as OTC options for the treatment of gastroesophageal reflux disease symptoms such as heartburn and acid regurgitation. Effective self-management of gastroesophageal reflux disease with OTC PPIs, e.g. omeprazole, could lead to lasting freedom from symptoms and improved quality of life for sufferers.